Company News 19 Dec 2024 Orthocell Submits U.S. FDA Regulatory Application Orthocell has announced the submission of its U.S. FDA 510(k) regulatory application for clearance to commercially distribute Remplirâ„¢ into the… Orthocell
Media 16 Dec 2024 Podcast | Frazis Capital Podcast Orthocell CEO & MD, Paul Anderson, recently joined Micahel Frazis on the Frazis Capital Podcast. Orthocell
Company News 12 Dec 2024 Orthocell Achieves Major Milestone with First Sales of Remplirâ„¢ in Singapore Orthocell has today announced the achievement of first sales of Remplirâ„¢ in Singapore, marking another significant milestone in its global commercialisation… Orthocell
Media 03 Dec 2024 The Australian Financial Review | Perth’s billionaires pile into medtech Orthocell Orthocell has been featured in The Australian Financial Review in an article by Health Editor Michael Smith titled “Perth’s billionaires… Orthocell
Company News 02 Dec 2024 Orthocell successfully completes US FDA 510(k) regulatory study for Remplirâ„¢ Orthocell has today reached another significant milestone with the successful completion of its Remplirâ„¢ 510(k) nerve repair regulatory study, validating… Orthocell
Media 02 Dec 2024 The Australian Business Review | Orthocell leaps closer to FDA approval after pivotal nerve-repair product study success Orthocell has been featured in The Australian Business Review, following today’s announcement that the US FDA 510(k) regulatory study of… Orthocell
